Europe Medical Cannabis Market Size, Share, Demand & Forecast 2025-2033
Market Overview 2025-2033
The Europe medical cannabis market size reached USD 2,586.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 12,652.9 Million by 2033, exhibiting a growth rate (CAGR) of 18.33% during 2025-2033. The market is growing due to increasing legalization, rising medical applications, and expanding research initiatives. Innovations in product development, regulatory support, and patient demand are driving expansion, making it a dynamic and evolving industry.
Key Market Highlights:
✔️ Rapid market growth driven by increasing legalization and acceptance of cannabis for medical use
✔️ Rising demand for cannabis-based treatments in pain management, neurology, and oncology
✔️ Expanding research and investment in pharmaceutical-grade cannabis production and innovation
Request for a sample copy of the report: https://www.imarcgroup.com/europe-medical-cannabis-market/requestsample
Europe Medical Cannabis Market Trends and Drivers:
The European medical cannabis market is rapidly growing due to new regulations. Countries like Germany, the UK, and Portugal have made it easier to prescribe medical cannabis. In 2024, Germany updated its narcotics laws. This change widened patient eligibility. Now, doctors can prescribe cannabis for chronic pain, multiple sclerosis, and chemotherapy-related nausea. They no longer need strict prior approval. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) fast-tracked approvals for cannabis-based medicinal products (CBMPs) in early 2024.
This led to a 35% increase in patient registrations year-on-year. These regulatory changes are reducing stigma. They allow pharmacies to stock CBMPs more easily and encourage doctors to include cannabis in treatment plans. However, not all regions are progressing equally. Southern and Eastern European countries are still held back by conservative policies. This creates a fragmented landscape across the region. Chronic pain disorders are driving the demand for medical cannabis. Opioid alternatives are gaining popularity amid Europe’s public health crisis. A 2024 report from the European Pain Federation shows that 22% of chronic pain patients now use cannabis therapies. This is up from 12% in 2022, showing more physician support.
Germany and the Netherlands are leading this trend. Insurers in these countries are covering cannabis-based medicine products (CBMPs) for conditions like fibromyalgia and neuropathic pain. The demand is also rising due to aging populations, with over 20% of Europe’s population aged 65 and older. Awareness of cannabis’s role in reducing opioid dependency is growing. In 2024, clinical trials in France and Spain showed a 40% drop in opioid use among patients using THC-CBD blends. This has led hospitals to adopt cannabis-based pain management guidelines.
Technological advancements and vertical integration are reshaping Europe’s cannabis supply chain. Licensed producers like Aurora Cannabis and Tilray are heavily investing in automated indoor farms in Denmark and Portugal. They use AI-driven climate control to boost cannabinoid yields. In 2024, these farms cut production costs by 25%. This allows for competitive pricing on high-THC strains aimed at neurological disorders. At the same time, product innovation is speeding up. Sublingual strips, nano-emulsified oils, and low-dose transdermal patches are now common in pharmacies. These products meet precise dosing needs.
The EU’s Novel Food Regulation, updated in late 2024, has encouraged R&D. It clarifies compliance for cannabinoid-infused edibles and drinks. This shift is drawing in new players, like beverage companies and wellness brands. They want to tap into the €3.2 billion medical cannabis market expected by 2026. The Europe medical cannabis market is characterized by rapid consolidation and cross-border collaboration.
Multinational drug companies are buying regional growers to secure supply chains. A clear example is Jazz Pharmaceuticals’ 2024 purchase of a majority stake in Germany’s Cannamedical. At the same time, telehealth platforms like HelloMD Europe are helping patients in rural areas. They offer virtual consultations where specialists are hard to find. Research partnerships between universities and producers are also thriving. For instance, a 2024 study from the University of Amsterdam found terpene synergies that boost CBD’s anti-inflammatory effects.
This discovery may lead to new formulations. However, challenges still exist, like reimbursement issues and varying quality standards. The European Cannabis Council’s 2024 initiative aims to solve these problems. It will create EU-wide testing protocols and THC labeling rules. With patient registrations exceeding 1.2 million and growing clinical evidence, the market is set for steady growth. Still, regulatory alignment is key to realizing its full potential.
Europe Medical Cannabis Market Segmentation:
The report segments the market based on product type, distribution channel, and region:
Study Period:
Base Year: 2024
Historical Year: 2019-2024
Forecast Year: 2025-2033
Breakup by Species:
Indica
Sativa
Hybrid
Breakup by Derivative:
Cannabidiol (CBD)
Tetrahydrocannabinol (THC)
Others
Breakup by Application:
Cancer
Arthritis
Migraine
Epilepsy
Others
Breakup by End Use:
Pharmaceutical Industry
Research and Development Centers
Others
Breakup by Route of Administration:
Oral Solutions and Capsules
Smoking
Vaporizers
Topicals
Others
Breakup by Country:
Germany
France
United Kingdom
Italy
Spain
Others
Competitive Landscape:
The market research report offers an in-depth analysis of the competitive landscape, covering market structure, key player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant. Additionally, detailed profiles of all major companies are included.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Comments
Post a Comment